$120M
The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.
"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
C
CellCentric—United KingdomRA Capital + 3 others